News & Views
Ipsen to buy biopharmaceutical company Epizyme for $247m
Medicine
29 June 2022
The transaction is focused on Epizyme’s lead asset, Tazverik (tazemetostat), a chemotherapy-free EZH2a inhibitor. Currently, the drug is indicated to treat metastatic or locally advanced epithelioid sarcoma in adults and paediatric patients aged 16 years and above who are not eligible for complete resection and adult patients with relapsed or refractory follicular lymphoma (FL) without any alternative treatment options.
Read more
Hydrogen-powered trains to be used in Germany’s capital region
Energy
29 June 2022
Siemens Mobility, which is a separately managed company of industrial giant Siemens, said the trains would provide “completely CO2 emission-free mobility” and have a top speed of 160 kilometers per hour (around 99 mph).
Read more
How to join Oxentt ?
To join the exclusive Business Agency elite group does not require important financial contribution. It is, however, imperative that by joining all members adhere to its philosophy of ethics, respect and seriousness.
Any business owner from any country, investor, entrepreneur and corporate executives are welcome to join us.
Watch how the Members’ interface Works
Dive into the world of Oxentt and discover how easy and direct is the way to reach out, communicate and cooperate with other members in your own city or throughout the world, online or in real life.
A dozen of features help you invite fellow members or all followers of Oxentt to any event you organize.
Receive a daily digest of international economic and business news dedicated to your own industry or any other industries by geographic area or globally.
Create your own group by area or by business sector and organize online or offline reunions.
Use text messaging or voice and video calls, one-to-one or by group, 100% secured.